AzTrials
AzTrials

Spontaneous Coronary Artery DissectionNorDen-SCAD ExNCT07785765

Norwegian Danish Spontaneous Coronary Artery Dissection Exercise Study

A study testing High intensity interval training (HIIT) in people with Spontaneous Coronary Artery Dissection and Myocardial Infarction (MI), run by Oslo University Hospital at 1 site in Norway.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this randomized clinical trial is to determine whether a supervised high-intensity interval training (HIIT) program can safely improve cardiorespiratory fitness and overall health in adults who have previously had spontaneous coronary artery dissection (SCAD), a non-atherosclerotic cause of heart attack… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
High intensity interval training (HIIT)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
1 siteNorway
Study dates
1 Jan 2027to 1 Jun 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Confirmed SCAD, at least 12 weeks since last event, age 18 years or older, medically stable and cleared for CPET and supervised exercise

Who cannot join

  • Disease with exercise restrictions, exercise related severe hypertension on CPET (>220 mmHg in Systolic blood pressure or >110mmHg in Diastolic blood pressure)

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Norway1 site
  • Rikshospitalet, Department of Cardiology, ProCardio Center for Innovation

    Oslo, 0372

Other trials in Norway

About this study

The goal of this randomized clinical trial is to determine whether a supervised high-intensity interval training (HIIT) program can safely improve cardiorespiratory fitness and overall health in adults who have previously had spontaneous coronary artery dissection (SCAD), a non-atherosclerotic cause of heart attack that often affects younger women.

Participants are women and men aged 18 years or older, with a confirmed SCAD at least 12 weeks before enrollment, who are medically stable, cleared for exercise testing, and able to attend supervised sessions.

Read more

The main questions the study aims to answer are:

  • Does a 12-week supervised HIIT program lead to a greater improvement in cardiorespiratory fitness (measured as peak oxygen uptake (VO2peak, ml/kg/min)) compared with usual care, without increasing the occurrence of major adverse cardiovascular events (MACE)?
  • Is a 12-week HIIT program safe for people with prior SCAD, assessed by the occurrence of MACE?

Researchers will compare two randomized groups (1:1):

  • Group A (HIIT): Participants take part in a supervised treadmill-based high-intensity interval training program twice per week for 12 weeks, with continuous heart rate monitoring and clear rules for stopping in case of symptoms.
  • Group B (usual care): Participants continue with the exercise advice they have already received after SCAD, without a structured supervised program and with a recommendation to avoid high-intensity exercise (above 85% of maximum heart rate).

Participants in both groups will:

  • Undergo cardiopulmonary exercise testing (CPET) at baseline and after 12 weeks to measure VO2peak and blood pressure response during exercise.
  • Have blood tests (for example cholesterol and cardiac biomarkers), blood pressure, heart rate and weight measured.
  • Complete validated questionnaires on quality of life (World Health Organization Quality of Life-BREF (WHOQOL-BREF)), anxiety (Generalized Anxiety Disorder 7-item scale (GAD-7)), and depression (Patient Health Questionnaire-9 (PHQ-9)).
  • Have activity data recorded using the MIA activity-tracking app and heart rate data will be uploaded simultaneously from portable devices.

Safety will be monitored continuously. Major adverse cardiovascular events (MACE), including death, recurrent heart attack (SCAD or non-SCAD), heart failure, stroke or transient ischemic attack, extracoronary arterial dissection, cardioversion or implantable cardioverter-defibrillator (ICD) therapy, will be recorded during the 12-week intervention and a 25-week follow-up period (total study duration per participant: 37 weeks).

Read the detailed description

Spontaneous coronary artery dissection (SCAD) is a non-atherosclerotic cause of acute coronary syndrome that predominantly affects younger, otherwise healthy women. It is characterized by a dissection and/or intramural hematoma in the coronary artery wall, leading to impaired coronary blood flow and myocardial infarction. SCAD typically occurs in women around the perimenopausal period, but a substantial proportion of patients are even younger, and SCAD is a leading cause of pregnancy-associated myocardial infarction. Traditional cardiovascular risk factors are often absent, whereas conditions such as fibromuscular dysplasia and migraine are more common. Emotional stress, and to a lesser extent physical stress, is frequently reported around the time of the event. This profile makes SCAD a distinctly sex-related cardiovascular disease: female-dominated, closely linked to hormonal transitions, non-atherosclerotic, and often preceded by severe psychosocial stress.

In contrast to other forms of coronary disease, evidence-based guidance on exercise and cardiac rehabilitation after SCAD is lacking. Most recommendations are extrapolated from atherosclerotic coronary disease and do not reflect the different risk profile and rehabilitation needs of SCAD survivors. Many patients are advised to avoid high-intensity exercise based on precaution rather than data, and structured rehabilitation is frequently omitted. Observational data suggest that fewer than half of SCAD patients meet general physical activity recommendations, and preliminary findings from the Norwegian Spontaneous Coronary Artery Dissection study (NOR-SCAD) indicate that many have lost physical fitness and do not reach age-expected peak oxygen uptake (VO2peak, ml/kg/min). Restrictive advice may therefore contribute to inactivity, loss of fitness, weight gain, persistent symptoms, and psychological distress, including fear of exertion and anxiety about recurrence. Importantly, there are no robust data demonstrating that usual physical activity increases the risk of recurrent SCAD. This combination of a predominantly female, younger patient group, a strong need for rehabilitation, and limited evidence on exercise safety creates a major gap in sex-specific cardiovascular care.

The Norwegian Spontaneous Coronary Artery Dissection Exercise trial (NOR-SCAD-Ex) is a randomized controlled trial conducted in Norway to address this evidence gap. Adult women and men aged ≥18 years with prior, confirmed SCAD at least 12 weeks before enrollment, who are medically stable and cleared for cardiopulmonary exercise testing (CPET) and supervised exercise, are eligible. After baseline assessments, participants are randomized 1:1 to either a 12-week supervised, treadmill-based high-intensity interval training (HIIT) program or usual care with an upper intensity restriction. All participants receive guideline-directed medical therapy and standard clinical follow-up independent of group allocation. CPET is performed at baseline and at 12 weeks using standardized procedures for calibration, performance, and quality control. VO2peak is defined as the highest 30-second average of oxygen uptake (ml/kg/min) during CPET. In addition to CPET, participants undergo blood pressure and heart rate measurements, routine blood tests (including lipids and cardiac biomarkers), and complete validated patient-reported outcome measures: quality of life (World Health Organization Quality of Life-BREF (WHOQOL-BREF)), anxiety (Generalized Anxiety Disorder 7-item scale (GAD-7)), depression (Patient Health Questionnaire-9 (PHQ-9)) and relevant symptom questionnaires.

The HIIT intervention consists of supervised sessions delivered by trained physiotherapists, typically using treadmill walking or running with individualized speed and incline. Each session includes a warm-up period at low-to-moderate intensity, followed by repeated 4-minute high-intensity intervals targeting approximately 85-95% of peak heart rate or Borg scale ratings of 15-18, interspersed with active recovery periods at about 60-70% of peak heart rate (Borg 11-13). Heart rate is monitored continuously using portable devices to document training intensity and adherence. Participants and physiotherapists are instructed to stop exercise immediately if chest pain, dizziness, palpitations or other symptoms suggestive of cardiovascular intolerance occur, and prespecified rules guide modification or termination of sessions.

Participants allocated to usual care do not receive a structured supervised exercise program during the 12-week intervention period. They are advised to continue their usual physical activity patterns but to avoid high-intensity exercise, defined as sustained effort above 85% of maximum heart rate. To characterize real-world exercise behavior in the control group, participants are provided with heart rate monitors and simple training diaries to record type, duration, and perceived intensity of physical activity. This allows detailed comparison of physical activity patterns between groups and assessment of potential contamination (high-intensity training) in the usual care arm.

Safety is a central focus of the study. Eligibility criteria include exclusion of conditions with strict exercise restrictions (such as major heritable aortic diseases), exercise-induced severe hypertension (e.g. systolic blood pressure > 220 mmHg) or complex ventricular arrhythmias during baseline CPET (e.g. non-sustained ventricular tachycardia >3 beats), and current pregnancy. Safety is monitored throughout the 12-week intervention and an additional 25-week follow-up period (total study duration per participant: 37 weeks). Major adverse cardiovascular events (MACE) including death, recurrent myocardial infarction (SCAD or non-SCAD), heart failure, stroke or transient ischemic attack, extracoronary artery dissection, cardioversion, and implantable cardioverter-defibrillator therapy, as well as serious adverse events and clinically significant arrhythmias, are systematically recorded and adjudicated. A Data Monitoring Committee (DMC) regularly reviews unblinded safety data and applies predefined stopping rules, including a Bayesian-based safety stopping rule, to ensure that the trial can be modified or terminated if unacceptable risk emerges.

Beyond the primary focus on VO2peak and MACE, the trial incorporates exploratory evaluation of blood pressure responses to exercise, including hypertensive response to exercise (HRE), and their potential sex-specific implications. HRE, quantified using systolic blood pressure relative to workload, may unmask latent hypertension and has been associated with future cardiovascular events independent of resting blood pressure. Because SCAD is a female-dominated, non-atherosclerotic coronary disease with reported overlaps with pregnancy complications and other vascular disorders, HRE may help identify subgroups with increased vascular risk who could benefit from targeted follow-up. The study also uses digital tools (such as the MIA activity-tracking app and portable heart rate monitors) to characterize physical activity patterns and heart rate responses in everyday life, providing additional insight into how SCAD survivors engage in exercise under different recommendations.

The overarching hypothesis is that a carefully supervised HIIT program will produce clinically meaningful improvements in cardiorespiratory fitness (a between-group difference in VO2peak of at least 2.5 ml/kg/min) compared with usual care, without an unacceptable increase in MACE. Secondary and exploratory hypotheses include that HIIT will improve quality of life and reduce symptoms of anxiety and depression, that supervised exercise training will favorably modify HRE and other cardiovascular risk markers, and that structured rehabilitation can reduce fear of exertion and support a safe return to physical activity in this vulnerable, predominantly female patient population. By integrating objective measures of fitness, blood pressure, and activity with patient-reported outcomes and rigorous safety monitoring, NOR-SCAD-Ex aims to provide the first randomized evidence on the efficacy and safety of HIIT after SCAD in Norway and to inform future, SCAD-specific exercise and rehabilitation recommendations.

Being tested
High intensity interval training (HIIT)
Keywords
SCAD, Exercise, HIIT, MACE, Spontaneous coronary artery dissection, High intensity interval training
Medical subject headings
Coronary Artery Dissection, Spontaneous, Myocardial Infarction, Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • High intensity interval training (HIIT)Other

    Participants take part in a supervised treadmill-based high-intensity interval training program twice per week for 12 weeks. Each session is 4 minutes x 4 at target heart rate between 85-95% of maximum HR.

Study groups in NCT07785765
Study groupRoleWhat they receive
Group A - High intensity interval training (HIIT)ExperimentalIntervention
Receives: Other: High intensity interval training (HIIT)
Group B - Usual CareNo interventionUsual care with exercise restriction

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from baseline to 12 weeks in peak oxygen uptake (VO2peak, ml/kg/min) measured by CPET

    Measured: From enrollment to the end of intervention (12 weeks)

Secondary outcomes (9)
  1. MACE (composite of recurrent SCAD, TIA/stroke, extra-coronary artery dissection,death and/or aborted cardiac arrest)

    Safety endpoint. Incidence of MACE (composite of recurrent SCAD, TIA/stroke, extra-coronary artery dissection,death and/or aborted cardiac arrest).

    Measured: From enrollment to end of follow-up period (12 weeks + 25 weeks)

  2. Incidence of MACE (recurrent SCAD alone)

    Safety endpoint. Incidence of MACE (recurrent SCAD alone)

    Measured: From enrollment to end of follow-up period (12 weeks + 25 weeks)

  3. Incidence of MACE (death or aborted cardiac arrest)

    Safety endpoint. Incidence of MACE (death or aborted cardiac arrest)

    Measured: From enrollment to end of follow-up period (12 weeks + 25 weeks)

  4. Change in quality of life

    Quality of Life assessed by validated questionnaire: World Health Organization Quality of Life-BREF (WHOQOL-BREF)

    Measured: From enrollment to end of intervention (12 weeks)

  5. Change in depression

    Change in depression assessed by validated questionnaire: Patient Health Questionnaire-9 (PHQ-9)

    Measured: From enrollment to end of intervention (12 weeks)

  6. Change in anxiety

    Change in anxiety measured by validated questionnaire: Generalized Anxiety Disorder 7-item scale (GAD-7)

    Measured: From enrollment to end of intervention (12 weeks)

  7. Changes in blood pressure at rest and hypertensive response to exercise (HRE)

    HRE will be measured during cardio-pulmonary-exercise test (CPET) before and after study intervention (12 weeks) in both HIIT-group and usual care-group. The trial will use HRE relative to fitness (SBT/METs) and will be tested at predefined points (low, moderat and high intensity) during a modified Balke protocol.

    Measured: From enrollment to end of study intervention (12 weeks)

  8. Changes in weight

    weight (kg) measured before and after intervention

    Measured: From enrollment to end of study intervention (12 weeks)

  9. Change in lipid profile

    Change in lipid profile (Total cholesterol, LDL, HDL) in mmol/L

    Measured: From enrollment to end of study intervention (12 weeks)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Aug 2026
  2. Study start1 Jan 2027 (estimated)
  3. Primary completion1 Jan 2028 (estimated)
  4. Study completion1 Jun 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07785765
Sponsor's protocol ID
REKnr 975719
Acronym
NorDen-SCAD Ex
Status last verified
Aug 2026
First submitted
14 Aug 2026
Last updated
25 Aug 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: No plan to share individual participant data (IPD). Due to ethical and privacy considerations and limitations in the current consent and data governance framework, only aggregate (summary) results will be shared through publications and posting on ClinicalTrials.gov.

Publications

  • Hilton SE, Thiessen JS, Rycroft AD, Miners NI, Bommarito JC, Matharu TS, Khangura PK, Stapleton RK, Rocha LC, Nardone M, Millar PJ. Influence of sex and aerobic fitness on blood pressure during maximal treadmill exercise in young healthy adults. J Appl Physiol (1985). 2025 Jun 1;138(6):1321-1326. doi: 10.1152/japplphysiol.00056.2025. Epub 2025 May 5.

    PubMed 40323584
  • Schultz MG, Otahal P, Roberts-Thomson P, Stanton T, Hamilton-Craig C, Wahi S, La Gerche A, Hare JL, Selvanayagam J, Maiorana A, Venn AJ, Marwick TH, Sharman JE. Exercise blood pressure relative to fitness and cardiovascular outcomes: the EXERTION study. Eur Heart J. 2026 Apr 7;47(14):1661-1671. doi: 10.1093/eurheartj/ehaf1082.

    PubMed 41528824
  • De Backer J, Haugaa KH, Hasselberg NE, de Hosson M, Brida M, Castelletti S, Cauldwell M, Cerbai E, Crotti L, de Groot NMS, Estensen ME, Goossens ES, Haring B, Kurpas D, McEniery CM, Peters SAE, Rakisheva A, Sambola A, Schlager O, Schoenhoff FS, Simoncini T, Steinbach F, Sudano I, Swan L, Valente AM; ESC Scientific Document Group. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. Eur Heart J. 2025 Nov 14;46(43):4462-4568. doi: 10.1093/eurheartj/ehaf193. No abstract available.

    PubMed 40878294
  • Heath A, Offringa M, Pechlivanoglou P, Rios JD, Klassen TP, Poonai N, Pullenayegum E; KidsCAN PERC Innovative Paediatric Clinical Trials Team. Determining a Bayesian predictive power stopping rule for futility in a non-inferiority trial with binary outcomes. Contemp Clin Trials Commun. 2020 Apr 8;18:100561. doi: 10.1016/j.conctc.2020.100561. eCollection 2020 Jun.

    PubMed 32300671
  • Tucker WJ, Fegers-Wustrow I, Halle M, Haykowsky MJ, Chung EH, Kovacic JC. Exercise for Primary and Secondary Prevention of Cardiovascular Disease: JACC Focus Seminar 1/4. J Am Coll Cardiol. 2022 Sep 13;80(11):1091-1106. doi: 10.1016/j.jacc.2022.07.004.

    PubMed 36075680
  • Kavanagh T, Mertens DJ, Hamm LF, Beyene J, Kennedy J, Corey P, Shephard RJ. Peak oxygen intake and cardiac mortality in women referred for cardiac rehabilitation. J Am Coll Cardiol. 2003 Dec 17;42(12):2139-43. doi: 10.1016/j.jacc.2003.07.028.

    PubMed 14680741
  • Stensvold D, Viken H, Steinshamn SL, Dalen H, Stoylen A, Loennechen JP, Reitlo LS, Zisko N, Baekkerud FH, Tari AR, Sandbakk SB, Carlsen T, Ingebrigtsen JE, Lydersen S, Mattsson E, Anderssen SA, Fiatarone Singh MA, Coombes JS, Skogvoll E, Vatten LJ, Helbostad JL, Rognmo O, Wisloff U. Effect of exercise training for five years on all cause mortality in older adults-the Generation 100 study: randomised controlled trial. BMJ. 2020 Oct 7;371:m3485. doi: 10.1136/bmj.m3485.

    PubMed 33028588
  • Mueller S, Winzer EB, Duvinage A, Gevaert AB, Edelmann F, Haller B, Pieske-Kraigher E, Beckers P, Bobenko A, Hommel J, Van de Heyning CM, Esefeld K, von Korn P, Christle JW, Haykowsky MJ, Linke A, Wisloff U, Adams V, Pieske B, van Craenenbroeck EM, Halle M; OptimEx-Clin Study Group. Effect of High-Intensity Interval Training, Moderate Continuous Training, or Guideline-Based Physical Activity Advice on Peak Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA. 2021 Feb 9;325(6):542-551. doi: 10.1001/jama.2020.26812.

    PubMed 33560320
  • Battenberg AE, Carey P, Larson KF, Hayes SN, Smith JR, Baker SE, Bonikowske AR, Tweet MS. Spontaneous Coronary Artery Dissection in Highly Active Individuals: Insights From a Prospective Registry. JACC Adv. 2026 Feb;5(2):102485. doi: 10.1016/j.jacadv.2025.102485. Epub 2026 Jan 2.

    PubMed 41483544
  • Chacin-Suarez AS, Bonikowske AR, Medina-Inojosa JR, Gulati R, Best PJ, Hayes SN, Tweet MS. Physical Activity and Exercise Patterns After Spontaneous Coronary Artery Dissection: Insights From a Large Multinational Registry. Front Cardiovasc Med. 2021 Jun 15;8:642739. doi: 10.3389/fcvm.2021.642739. eCollection 2021.

    PubMed 34212011
  • Kim SK, Wing-Lun E, Chandrasekhar J, Puri A, Burgess S, Ford TJ, Kovacic J, Graham RM, Psaltis PJ, Zaman S. The Australian New Zealand Spontaneous Coronary Artery Dissection (ANZ-SCAD) Registry - A Multi-Centre Cohort Study: Protocol, Background and Significance. Heart Lung Circ. 2022 Dec;31(12):1612-1618. doi: 10.1016/j.hlc.2022.08.018. Epub 2022 Sep 28.

    PubMed 36180304
  • Saw J, Starovoytov A, Aymong E, Inohara T, Alfadhel M, McAlister C, Samuel R, Grewal T, Parolis JA, Sheth T, So D, Minhas K, Brass N, Lavoie A, Bishop H, Lavi S, Pearce C, Renner S, Madan M, Welsh RC, McGrath BM, Vijayaraghavan R, Har B, Ibrahim R, Chaudhary P, Ganesh SK, Graham J, Matteau A, Martucci G, Ko DT, Humphries K, Mancini GJ. Canadian Spontaneous Coronary Artery Dissection Cohort Study: 3-Year Outcomes. J Am Coll Cardiol. 2022 Oct 25;80(17):1585-1597. doi: 10.1016/j.jacc.2022.08.759.

    PubMed 36265953

Questions about this trial

What is this clinical trial studying?

A study testing High intensity interval training (HIIT) in people with Spontaneous Coronary Artery Dissection and Myocardial Infarction (MI), run by Oslo University Hospital at 1 site in Norway.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 25 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from baseline to 12 weeks in peak oxygen uptake (VO2peak, ml/kg/min) measured by CPET (time frame: From enrollment to the end of intervention (12 weeks)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07785765, which also lists 12 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Aug 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in